Carvedilol phosphate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412413

CAS#: 610309-89-2

Description: Carvedilol phosphate has alpha as well as beta blocking activity.

Chemical Structure

Carvedilol phosphate
CAS# 610309-89-2

Theoretical Analysis

MedKoo Cat#: 412413
Name: Carvedilol phosphate
CAS#: 610309-89-2
Chemical Formula: C48H60N4O17P2
Exact Mass: 1026.3429
Molecular Weight: 1026.97
Elemental Analysis: C, 56.14; H, 5.89; N, 5.46; O, 26.48; P, 6.03

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Carvedilol phosphate; Coreg CR; SKF105517D; SKF-105517D; SKF 105517D

IUPAC/Chemical Name: bis(1-((9H-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol) bis(phosphate) hydrate


InChi Code: InChI=1S/2C24H26N2O4.2H3O4P.H2O/c2*1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;2*1-5(2,3)4;/h2*2-12,17,25-27H,13-16H2,1H3;2*(H3,1,2,3,4);1H2

SMILES Code: COc1c(OCCNCC(COc(ccc2)c3c2[nH]c4c3cccc4)O)cccc1.COc5c(OCCNCC(COc(ccc6)c7c6[nH]c8c7cccc8)O)cccc5.OP(O)(O)=O.OP(O)(O)=O.O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1026.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Polonini H, da Silva SL, Brandão MAF, Bauters T, De Moerloose B, Ferreira AO. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. Int J Pharm Compd. 2018 Nov-Dec;22(6):516-526. PMID: 30384353.

2: Allada R, Maruthapillai A, Palanisamy K, Chappa P. Moisture Sorption- desorption Characteristics and the Corresponding Thermodynamic Properties of Carvedilol Phosphate. J Pharm Bioallied Sci. 2017 Jan-Mar;9(1):16-21. doi: 10.4103/0975-7406.206216. PMID: 28584488; PMCID: PMC5450465.

3: Okumura K, Kato H, Honjo O, Breitling S, Kuebler WM, Sun M, Friedberg MK. Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. J Mol Med (Berl). 2015 Jun;93(6):663-74. doi: 10.1007/s00109-015-1251-9. Epub 2015 Jan 18. PMID: 25595602.

4: Oliveira PJ, Esteves T, Rolo AP, Palmeira CM, Moreno AJ. Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism. Cardiovasc Toxicol. 2004;4(1):11-20. doi: 10.1385/ct:4:1:11. PMID: 15034201.

5: Avachat AM, Patel KB, Rokade MS, Dash RR. Formulation and characterization of an expandable, gastroretentive system of carvedilol phosphate by 32 factorial design. PDA J Pharm Sci Technol. 2011 Jan-Feb;65(1):12-9. PMID: 21414936.

6: Yilmaz B, Arslan S. HPLC/Fluorometric Detection of Carvedilol in Real Human Plasma Samples Using Liquid-Liquid Extraction. J Chromatogr Sci. 2016 Mar;54(3):413-8. doi: 10.1093/chromsci/bmv157. Epub 2015 Nov 3. PMID: 26538492.

7: Yeh CH, Chen TP, Wang YC, Lin YM, Fang SW. Carvedilol treatment after myocardial infarct decreases cardiomyocytic apoptosis in the peri-infarct zone during cardioplegia-induced cardiac arrest. Shock. 2013 Apr;39(4):343-52. doi: 10.1097/SHK.0b013e31828c588a. PMID: 23481492.

8: Srikanth Meka V, Wee Liang VA, Dharmalingham SR, Sheshala R, Gorajana A. Preparation and in vitro characterization of non-effervescent floating drug delivery system of poorly soluble drug, carvedilol phosphate. Acta Pharm. 2014 Dec;64(4):485-94. doi: 10.2478/acph-2014-0038. PMID: 25531788.

9: Hashemzadeh M, Movahed MR, Russu WA, Soroush L, Hill DN. Novel design and synthesis of modified structure of carvedilol. Recent Pat Cardiovasc Drug Discov. 2011 Sep;6(3):175-9. doi: 10.2174/157489011797376988. PMID: 21834769.

10: Chakraborty S, Shukla D, Jain A, Mishra B, Singh S. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interface Sci. 2009 Jul 15;335(2):242-9. doi: 10.1016/j.jcis.2009.03.047. Epub 2009 Apr 5. PMID: 19403142.